Mathematical modeling of multi-drugs therapy

a challenge for determining the optimal combinations of antiviral drugs

Yoshiki Koizumi, Shingo Iwami

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

In the current era of antiviral drug therapy, combining multiple drugs is a primary approach for improving antiviral effects, reducing the doses of individual drugs, relieving the side effects of strong antiviral drugs, and preventing the emergence of drug-resistant viruses. Although a variety of new drugs have been developed for HIV, HCV and influenza virus, the optimal combinations of multiple drugs are incompletely understood. To optimize the benefits of multi-drugs combinations, we must investigate the interactions between the combined drugs and their target viruses. Mathematical models of viral infection dynamics provide an ideal tool for this purpose. Additionally, whether drug combinations computed by these models are synergistic can be assessed by two prominent drug combination theories, Loewe additivity and Bliss independence. By combining the mathematical modeling of virus dynamics with drug combination theories, we could show the principles by which drug combinations yield a synergistic effect. Here, we describe the theoretical aspects of multi-drugs therapy and discuss their application to antiviral research.

Original languageEnglish
Number of pages1
JournalTheoretical biology & medical modelling
Volume11
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Drug therapy
Drug Combinations
Viruses
Mathematical Modeling
Therapy
Antiviral Agents
Drugs
Drug Therapy
Pharmaceutical Preparations
Virus
Virus Diseases
Mathematical models
Orthomyxoviridae
Drug-Related Side Effects and Adverse Reactions
Theoretical Models
HIV
Research
Influenza
Additivity

All Science Journal Classification (ASJC) codes

  • Modelling and Simulation
  • Health Informatics

Cite this

@article{12bcad3e6c8f4528be268f8fd22e2fb0,
title = "Mathematical modeling of multi-drugs therapy: a challenge for determining the optimal combinations of antiviral drugs",
abstract = "In the current era of antiviral drug therapy, combining multiple drugs is a primary approach for improving antiviral effects, reducing the doses of individual drugs, relieving the side effects of strong antiviral drugs, and preventing the emergence of drug-resistant viruses. Although a variety of new drugs have been developed for HIV, HCV and influenza virus, the optimal combinations of multiple drugs are incompletely understood. To optimize the benefits of multi-drugs combinations, we must investigate the interactions between the combined drugs and their target viruses. Mathematical models of viral infection dynamics provide an ideal tool for this purpose. Additionally, whether drug combinations computed by these models are synergistic can be assessed by two prominent drug combination theories, Loewe additivity and Bliss independence. By combining the mathematical modeling of virus dynamics with drug combination theories, we could show the principles by which drug combinations yield a synergistic effect. Here, we describe the theoretical aspects of multi-drugs therapy and discuss their application to antiviral research.",
author = "Yoshiki Koizumi and Shingo Iwami",
year = "2014",
month = "1",
day = "1",
doi = "10.1186/1742-4682-11-41",
language = "English",
volume = "11",
journal = "Theoretical Biology and Medical Modelling",
issn = "1742-4682",
publisher = "BioMed Central",

}

TY - JOUR

T1 - Mathematical modeling of multi-drugs therapy

T2 - a challenge for determining the optimal combinations of antiviral drugs

AU - Koizumi, Yoshiki

AU - Iwami, Shingo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - In the current era of antiviral drug therapy, combining multiple drugs is a primary approach for improving antiviral effects, reducing the doses of individual drugs, relieving the side effects of strong antiviral drugs, and preventing the emergence of drug-resistant viruses. Although a variety of new drugs have been developed for HIV, HCV and influenza virus, the optimal combinations of multiple drugs are incompletely understood. To optimize the benefits of multi-drugs combinations, we must investigate the interactions between the combined drugs and their target viruses. Mathematical models of viral infection dynamics provide an ideal tool for this purpose. Additionally, whether drug combinations computed by these models are synergistic can be assessed by two prominent drug combination theories, Loewe additivity and Bliss independence. By combining the mathematical modeling of virus dynamics with drug combination theories, we could show the principles by which drug combinations yield a synergistic effect. Here, we describe the theoretical aspects of multi-drugs therapy and discuss their application to antiviral research.

AB - In the current era of antiviral drug therapy, combining multiple drugs is a primary approach for improving antiviral effects, reducing the doses of individual drugs, relieving the side effects of strong antiviral drugs, and preventing the emergence of drug-resistant viruses. Although a variety of new drugs have been developed for HIV, HCV and influenza virus, the optimal combinations of multiple drugs are incompletely understood. To optimize the benefits of multi-drugs combinations, we must investigate the interactions between the combined drugs and their target viruses. Mathematical models of viral infection dynamics provide an ideal tool for this purpose. Additionally, whether drug combinations computed by these models are synergistic can be assessed by two prominent drug combination theories, Loewe additivity and Bliss independence. By combining the mathematical modeling of virus dynamics with drug combination theories, we could show the principles by which drug combinations yield a synergistic effect. Here, we describe the theoretical aspects of multi-drugs therapy and discuss their application to antiviral research.

UR - http://www.scopus.com/inward/record.url?scp=84922116880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922116880&partnerID=8YFLogxK

U2 - 10.1186/1742-4682-11-41

DO - 10.1186/1742-4682-11-41

M3 - Article

VL - 11

JO - Theoretical Biology and Medical Modelling

JF - Theoretical Biology and Medical Modelling

SN - 1742-4682

ER -